## **OPEN PEER REVIEW REPORT 1**

Name of journal: Neural Regeneration Research

Manuscript NO: NRR-D-23-00021

Title: Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses,

and cells

Reviewer's Name: Eliana C B Toscano

Reviewer's country: Brazil

## **COMMENTS TO AUTHORS**

The mini-review highlighted the main academic and industrial research for identifying therapeutic strategies to treat neurodegenerative disorders, especially Alzheimer's disease. Since tau-related neurodegeneration remains progressive and without a cure, updates on the therapeutic strategies, even though in preclinical or clinical phases, are worthy of investigation. However, the authors should address a major revision:

- 1. References are missing, mainly in the introduction section.
- 2. The authors should describe better the main therapeutic mechanisms of the small molecules class addressed in table 1.
- 3. It is important to discuss the pathophysiological and clinical effects of E2814 frug in comparison with Ab monoclonal antibodies.
- 4. The authors should include a table in the sections "Innate immunity: microglia" and "Synaptic targets", selecting drugs whose tau-targeting evidence is more robust, even though in preclinical studies.
- 5. In the discussion section, it is important mentioning the main adverse effects of drugs in phase 3 of clinical trials, and consequent limitations for the treatment.
- 6. The authors should include a final paragraph, comprising a conclusion and future directions. Are the studies promising? What are the main gaps?